oprelvekin

{
  "id": "MLC-T-ONC-006115",
  "term": "oprelvekin",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to increase the number of blood cells, especially platelets, in some cancer patients receiving chemotherapy. Oprelvekin is a form of interleukin-11 (a cytokine normally made by support cells in the bone marrow) that is made in the laboratory. It is a type of biological response modifier. Also called Neumega, recombinant human interleukin-11, and rhIL-11.",
    "A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death. This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis."
  ],
  "abbreviation": "rhIL-11",
  "synonyms": [
    "Neumega",
    "recombinant human interleukin-11",
    "rhIL-11",
    "IL-11",
    "adipogenesis inhibitory factor",
    "interleukin 11",
    "therapeutic interleukin-11"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/oprelvekin/"
}